The bryostatins are macrocyclic lactones that represent an additional structural class of potent activators of protein kinase C. These marine animal biosynthetic products are of unusual interest because they induce only a subset of the biological responses induced by the phorbol esters. We have now determined the binding affinities of naturally occurring and semisynthetic bryostatins for protein kinase C by competition analysis with [26-3Hlbryostatin 4 as the radioactive ligand. Esterification of the hydroxyl group at C26 caused dramatic loss of activity as did inversion of the asymmetric center at this position. In contrast, neither of the ester groups at C7 and C20 had a major influence on activity. Computer modeling of the phorbol esters, related diterpenes, and indole alkaloids suggested that the C20, C9, and C4 oxygens of phorbol represented critical elements of the phorbol ester pharmacophore. The C26 oxygen of the bryostatins, together with the C1 and C19 oxygens, gave an excellent spatial correlation with this model, with a root-mean-square deviation of 0.16 A (compared to 0.10-0.35 A among phorbol-related diterpenes). The extension of the phorbol ester pharmacophore model to the bryostatins and its agreement with the structureactivity relations for the bryostatin class of compounds provide additional support for the validity of the model. Protein kinase C mediates one arm of the signal-transduction pathway proceeding through inositol phospholipid breakdown (1, 2) . This pathway is directly involved in the action of a broad range of cellular effectors, including growth factors and oncogenes, and indirectly affects other transduction pathways such as that of the cyclic AMP second-messenger system. Protein kinase C is proposed to be activated by 1,2-diacyl-sn-glycerol compounds and by certain exogenous analogs such as the phorbol ester tumor promoters (3, 4). In addition to the phorbol esters and related diterpenes, a number of structurally distinct natural products have been identified that also bind to protein kinase C with high affinity and that resemble the phorbol esters in their actions at nanomolar concentrations in biological systems. These compounds include the indole alkaloids such as teleocidin and the polyacetates such as aplysiatoxin (5) .
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Recently, considerable attention has focused on an unusual class of potent activators of protein kinase C, the bryostatins. These compounds are macrocyclic lactones isolated from Bugula neritina and other marine bryozoans on the basis of antineoplastic activity against the P388 leukemia cell system (6) . The bryostatins at nanomolar concentrations inhibit phorbol ester binding to protein kinase C and stimulate enzymatic activity in vitro to a comparable degree as do the phorbol esters (7) (8) (9) . Biologically, however, the bryostatins induce only a subset of the typical phorbol ester responses. Moreover, the bryostatins block, in an apparently noncompetitive fashion, the action of the phorbol esters on those responses that they themselves do not induce. Examples include differentiation in HL-60 promyelocytic leukemia cells (7, 10) , in Friend erythroleukemia cells (11) , and in primary mouse epidermal cells (12) ; arachidonic acid release in C3H1OT1/2 cells (13); and tumor promotion in mouse skin (14) . An understanding of the mechanism for the differences in bryostatin and phorbol ester action may permit selective intervention in the protein kinase C pathway.
The bryostatins demonstrate that structurally different activators of protein kinase C need not be functionally equivalent. For full exploration of the structure-function relations of the protein kinase C system, synthetically more accessible compounds than the potent naturally occurring activators would be of great value. As a guide to the design of such compounds, we have used computer comparison of the x-ray and/or calculated structures of the diterpene, indole alkaloid, and 1,2-diacyl-sn-glycerol classes of protein kinase C activators to identify the isospatial functional groups and hydrophobic regions that constitute the putative phorbol ester pharmacophore (15) . This approach suggested a critical role for the C4, C9, and C20 oxygens of phorbol. Based on this modeling, an initial series of benzyl alcohol and hydroxymethylindole derivatives were prepared that inhibited phorbol ester binding to protein kinase C and that showed effects on epidermal growth factor binding and phosphorylation in platelets similar to those of the phorbol esters (15) .
We report here on the structure-activity analysis for binding of natural and semisynthetic bryostatins to protein kinase C. The bryostatins yield an excellent fit to the pharmacophore model derived from the phorbol esters and indole alkaloids, and the experimental structure-activity relations are largely consistent with this model.
MATERIALS AND METHODS
Protein kinase C was purified from the brains of female CD-1 mice (Charles River Breeding Laboratories) through the concentration step after DE-52 chromatography as described by Jeng et al. (16) . The enzyme preparation was frozen in the presence of 10% (wt/vol) glycerol and stored at -70°C until use.
Bryostatins were isolated as described: bryostatin 1 (6), bryostatin 2 (17), bryostatin 3 (18), bryostatin 4 (19), bryostatins 5-7 (20) , bryostatin 8 (21), bryostatin 9 (22) , and bryostatin 10 (23). Bryostatin 4 13,30-epoxide and bryostatin 4 26-acetate were synthesized from bryostatin 4 as reported (23) . Preparation and characterization of [26-3H] The disks were washed with 10 ml of 55% (vol/vol) methanol/20 mM Tris chloride, pH 7.4/0.1 mM Ca2+ and chilled to 00C, and the radioactivity was measured. Nonspecific binding was measured in the absence of added enzyme. Free ligand was calculated from the difference between total ligand and that bound to the filter. Because the bryostatins are highly lipophilic ligands, it should be noted that "free ligand" will be present almost entirely in the detergent micelle and that nominal molar concentrations for dissociation constants will thus be inversely proportional to the detergent concentration. The bryostatins absorb avidly to surfaces when in aqueous solution. However, they are stable under our assay conditions in the presence of Triton X-100/phosphatidylserine. Inhibition of [3H]bryostatin 4 binding was determined for concentrations of nonradioactive bryostatin from 0.3 to 300 nM. The 50% inhibitory concentrations were determined from a computer fit of the binding data, and the dissociation constants were calculated from the 50% inhibitory concentrations as described (24) . Direct binding of [26-3H] bryostatin 4 and epi[26-3H]bryostatin 4 were measured as above except that the concentration of radioactive bryostatin was varied.
RESULTS

Inhibition of [3H]Bryostatin 4 Binding by Nonradioactive
Bryostatins. The naturally occurring bryostatin derivatives examined here ( Fig. 1 ) display marked variation in the length of the ester side chains. Moreover, individual derivatives are entirely lacking the ester group at 07 (bryostatin 2), are lacking the oxygen at C20 together with the associated ester group (bryostatin 10), or are esterified on the hydroxyl groups at C19 (bryostatin 3) and at C26. The relative binding affinities of the derivatives for protein kinase C were determined by competition with [26-3H] In contrast to phorbol, bryostatin 1 is characterized by a conformationally mobile 26-membered macrolide ring. The two compounds possess, however, a comparable arrangement of pharmacophoric groups. In particular, the hydroxyl group at C26 of bryostatin 1 represents a reasonable surrogate for the corresponding C20 hydroxyl of phorbol. The relationship of the C4 and C9 oxygens to the reference C20 oxygen in phorbol is then seen to be approximately that found for the C1 and C19 oxygens, respectively, to the C26 oxygen in bryostatin 1. Furthermore, comparison of bryostatin 1 and (S)-1,2-diacyl-sn-glycerol reveals a more obvious correspondence of subunits, with both possessing vicinal hydroxyalkyl, and ester groups (see Fig. 3) .
Quantification of the structural relationships among bryostatin 1, phorbol, and (S)-1,2-diacyl-sn-glycerol was accomplished by computer-assisted comparison of the respective pharmacophoric oxygens of the three types of protein kinase C activators. The coordinates of these oxygens in the phorbol esters and in 1,2-diacyl-sn-glycerol were obtained as described above from crystal structure data and/or calculations. Coordinates for all but the hydroxyethyl atoms of bryostatin 1 were derived from its crystal structure. Since the relative coordinates of the rotationally mobile hydroxyethyl atoms can vary, the relative energies of all conformations resulting from rotation about the C25-C26 bond were calculated (MMP2). Three low-energy conformers were produced corresponding to C24-C25-C26-O dihedral angles of 350, 1900, and 285°, the latter two corresponding closely to rotamers that coexist in the crystal structure. The coordinates of the pharmacophoric oxygens in these and other low-energy conformations of bryostatin 1 were then compared with the coordinates of the respective pharmacophoric oxygens in all three C6-C20 rotamers of phorbol. The best correlation was found between phorbol with a C7-C6-C20-O dihedral angle of 138°, previously referred to as phorbol model I, and bryostatin 1 with a C24-C25-C26-O dihedral angle of 3100, the latter corresponding to a conformation that is only 4.68 kcal/mol above the calculated global energy minimum. This correlation gave a root-meansquare deviation of fitted atoms of 0.16 A, which is well within the range of 0.10-0.35 A found in previous correlations of phorbol esters with other naturally occurring tumor promoters (15) . Furthermore, in addition to an excellent correlation of centers of mass of the pharmacophoric oxygens, a good alignment of orbitals was observed as is necessary for similar binding activity. Table 2 presents the correlation between bryostatin 1 and phorbol models I and II (differing by a rotation of 1200 about the C6-C20 bond). A significantly better correlation is obtained for phorbol model I, indicating that model I better describes the active conformation. Furthermore, it is expected that those structures previously shown to correlate well with phorbol model I should also correlate with bryostatin 1, although not necessarily as well. In fact, good correlations are obtained for (S)-1,2-diacyl-sn-glycerol, ingenol, gnidimacrin, dihydroteleocidin, and aplysiatoxin with bryostatin 1.
An additional requirement for biological activity according to our model is the presence of a lipophilic group in a region where it presumably affects binding orientation and partitioning of the molecule into the membrane (15) . In phorbol derivatives, a fatty acid is esterified to the C12 hydroxyl; in ingenol, an A-ring ester occupies the same region. While bryostatin 1 contains no long-chain ester in this area, the largely lipophilic body of the molecule does occupy the same region, thereby fulfilling this requirement. phorbol and C24 of teleocidin. However, it differs in being a secondary rather than a primary hydroxyl. Activity requires the R configuration at this position, and we do not know whether substituents larger than methyl group will be tolerated. The exciting possibility exists that substitution at this position can be used to lock the freely rotating hydroxyl in the optimal orientation for receptor interaction, enhancing binding potency, or that orientation might differentially affect binding to different enzymes. Since the S configuration is sterically restricted for binding, the methyl group may itself help limit rotation at this position when the bryostatin is bound to the enzyme and thereby contribute to the apparent high binding affinity observed for the bryostatins.
The aplysiatoxins, a structurally distinct class of protein kinase C activators, also possess a single exocyclic, secondary hydroxyl group. As in the bryostatins, this hydroxyl group (at C30) is in the R configuration (25) . Thus, the contribution ofthe methyl group to activity can potentially be assessed, since oscillatoxin A represents 20-desmethyldebromoaplysiatoxin. Consistent with expectations, oscillatoxin A was less potent for inducing mouse ear reddening and ornithine decarboxylase and for inhibiting [20-3H] degree to which they could cause arachidonic acid release or, reciprocally, block release induced by the phorbol esters (13) . Bryostatins 1 and 4 induced no more than 17% of the level induced by phorbol ester, whereas bryostatin 3 induced 61%, a finding again consistent with a role for the C19 hydroxyl in recognition.
The bryostatin binding to protein kinase C showed relatively little dependence on the length of the side chains at C7 and C20 under our assay conditions, where virtually all of the bryostatin will have partitioned into the lipid phase. The inflammatory potencies of ingenol 3-monoesters show similar behavior, with comparable activities for ingenol 3-butyrate and ingenol 3-hexadecanoate and 8-fold higher activity for ingenol 3-tetradecanoate (28) .
The extension of the phorbol ester pharmacophore model to the bryostatins provides further support for its general validity. However, it does not clarify why the bryostatins display a mixture of phorbol-ester agonistic and phorbolester antagonistic properties. One mechanism currently being evaluated is that the bryostatins both interact with protein kinase C at the high-affinity phorbol ester binding site to induce phorbol ester-like responses and also interact at a distinct target, not efficiently recognized by the phorbol esters, to suppress protein kinase C responses. Indirect evidence for this model is that bryostatins inhibit phorbol ester action noncompetitively in Friend erythroleukemia cells (11) and induce in HL-60 promyelocytic leukemia cells unique phosphoproteins as well as all those induced by phorbol ester (29) . If this second target exists, it might represent either a distinct bryostatin receptor or, alternatively, a form of protein kinase C modified to recognize phorbol esters only weakly. The structural features requisite for the unique bryostatin effects are only beginning to be explored.
